OPEN ACCESS
NIJBAS
Publications 2025
ONLINE ISSN: 2992-5797
PRINT ISSN: 2992-6122

NEWPORT INTERNATIONAL JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES (NIJBAS)

Volume 7 Issue 2 Page 66-72, 2026

https://doi.org/10.59298/NIJBAS/2026/7.2.6672

Toxicokinetics of Phytotherapeutic Agents: Balancing Antioxidant Activity with Safety

Zakaria Ali

Department of Pharmacy Kampala International University Uganda
Email:ali.zakaria@studwc.kiu.ac.ug

ABSTRACT

Phytotherapeutic agents - bioactive compounds derived from plants - have long been used in traditional and modern medicine due to their antioxidant, anti-inflammatory, and therapeutic properties. However, despite their benefits, there is growing concern regarding their safety profiles, especially at higher doses or prolonged use. Toxicokinetics - the study of how a substance enters, moves through, and leaves the body - is crucial for understanding both the therapeutic potential and risk factors associated with these natural compounds. This review examines the toxicokinetic processes of phytotherapeutic agents, including absorption, distribution, metabolism, and excretion (ADME), and evaluates how these processes influence safety and efficacy. The article also explores factors affecting toxicokinetics such as chemical structure, dose, formulation, age, and genetic differences. Common challenges - such as herb-drug interactions, metabolic transformation to toxic metabolites, and accumulation in tissues - are discussed. Strategies to improve safety without compromising antioxidant effectiveness include optimizing formulation, monitoring biomarkers, and applying advanced modeling techniques. By integrating toxicokinetic research with clinical practice, healthcare professionals and researchers can better balance the antioxidant benefits of plant compounds with their potential risks, promoting safer and more effective use of phytotherapeutic agents.

Keywords: Phytotherapeutic agents, Toxicokinetics, Antioxidant activity, Safety assessment, Herb-drug interactions

INTRODUCTION

Phytotherapeutic agents are plant-derived compounds used for the prevention and treatment of diseases and have formed the foundation of traditional medical systems across many cultures for centuries [1-5]. These agents include diverse classes of bioactive compounds such as flavonoids, including quercetin and catechins, phenolic acids such as caffeic acid, terpenoids such as ginsenosides, alkaloids, and carotenoids [6-9]. A key feature of many phytotherapeutic agents is their antioxidant activity, which enables them to scavenge reactive oxygen species, chelate pro-oxidant metal ions, and modulate endogenous antioxidant defense systems [10-14]. Through these mechanisms, they play an important role in reducing oxidative stress, a biological process strongly associated with aging and the pathogenesis of chronic diseases including cardiovascular disorders, diabetes, neurodegenerative conditions, and cancer [15-18]. Despite their widespread use and general perception as safe due to their natural origin, phytotherapeutic agents can produce complex and sometimes unpredictable biological effects [19-24]. Their safety and efficacy are influenced by factors such as dose, duration of use, formulation, and individual patient characteristics. Understanding toxicokinetics, which describes the absorption, distribution, metabolism, and excretion of compounds within the body, is therefore essential [25-30]. Toxicokinetic evaluation provides critical insight into how phytotherapeutic agents achieve therapeutic concentrations, how long they persist in tissues, and

under what conditions they may pose toxic risks, enabling a more balanced assessment of benefit versus safety [31-34]. This review explores these questions, focusing on the balance between antioxidant benefits and safety concerns from a toxicokinetic perspective.

2. Core Concepts in Toxicokinetics

Toxicokinetics provides a framework for understanding how chemical substances interact with the body over time and is central to evaluating the safety of phytotherapeutic agents [35-38]. It is commonly described using the ADME model, which encompasses absorption, distribution, metabolism, and excretion. Each of these processes determines the concentration of a compound at its site of action and influences both its therapeutic efficacy and potential toxicity [39-43]. Because phytotherapeutic agents are often complex mixtures of bioactive constituents, their toxicokinetic behavior can be highly variable and influenced by numerous biological and physicochemical factors.

2.1 Absorption

Absorption refers to the movement of a compound from its site of administration, most commonly the gastrointestinal tract, into the systemic circulation [44-48]. For orally administered phytotherapeutic agents, absorption is affected by several factors including chemical structure, formulation, and dietary context. Lipophilicity and molecular size play key roles in membrane permeability, with moderately lipophilic compounds generally exhibiting better passive diffusion across intestinal epithelial cells [49-50]. However, excessive lipophilicity may also promote retention within membranes or binding to dietary lipids. Formulation strategies such as encapsulation, emulsions, or nano-based delivery systems can substantially enhance absorption by improving solubility and stability. The presence of food may either enhance or inhibit absorption, depending on whether the compound interacts with dietary fats, proteins, or fibers [51-53]. Curcumin illustrates these challenges, as it shows poor absorption when administered alone, but significantly improved bioavailability when combined with piperine, which inhibits intestinal and hepatic metabolism [54-57]. While enhanced absorption improves antioxidant efficacy, it may also increase systemic exposure and the risk of adverse effects at higher doses.

2.2 Distribution

Following absorption, phytotherapeutic agents are distributed throughout the body via the bloodstream. Distribution is influenced by factors such as tissue perfusion, affinity for specific tissues, and binding to plasma proteins [58-60]. Compounds that bind extensively to serum proteins such as albumin may have prolonged circulation times but reduced free concentrations. Some phytochemicals display selective tissue accumulation; for example, polyphenols may distribute widely, while fat-soluble terpenoids can accumulate in adipose tissue [61]. Such accumulation can extend biological half-life and increase the likelihood of delayed or cumulative toxicity during long-term use.

2.3 Metabolism

Metabolism, primarily occurring in the liver, converts phytotherapeutic agents into more water-soluble metabolites to facilitate elimination [16]. Phase I reactions introduce or expose functional groups, while phase II reactions conjugate these groups with endogenous molecules such as glucuronic acid or sulfate. Although metabolism often results in detoxification, it can also produce reactive intermediates. Certain flavonoids may form electrophilic quinones capable of inducing cellular damage if detoxification pathways are overwhelmed [17].

2.4 Excretion

Excretion eliminates parent compounds and metabolites mainly through renal and biliary pathways. Poorly water-soluble agents may be excreted slowly, increasing the risk of bioaccumulation [18]. Biliary excretion can promote enterohepatic recirculation, prolonging systemic exposure and influencing both efficacy and toxicity [19]. Understanding these processes is essential for predicting safe dosing regimens of phytotherapeutic agents.

4. Toxicokinetic Challenges and Safety Concerns

Although antioxidants from plant sources are widely regarded as beneficial, several toxicokinetic challenges can limit their safety and therapeutic reliability [20]. These challenges arise from the complex way phytotherapeutic agents are absorbed, metabolized, distributed, and eliminated, and they become particularly important with high-dose or long-term use.

4.1 Poor Bioavailability and Variable Absorption

A major limitation of many plant-derived antioxidants is their poor and highly variable bioavailability [21]. Many polyphenols and related compounds exhibit low solubility, instability in the gastrointestinal tract, or extensive first-pass metabolism, resulting in limited systemic availability [22]. Consequently, higher oral doses are often required to achieve measurable biological effects. However, increasing the dose may overwhelm intestinal transporters or hepatic metabolic pathways, leading to disproportionate increases in systemic exposure [23]. This non-linear

behavior raises safety concerns, as excessive concentrations can increase the risk of toxicity even for compounds generally regarded as safe at lower doses.

4.2 Metabolic Transformation to Toxic Metabolites

Metabolism is usually a protective process that facilitates elimination, but it can also generate toxic intermediates [24]. Some flavonoids undergo oxidative metabolism to form reactive quinones or semiquinones, which can promote oxidative stress rather than alleviate it. These reactive species may covalently bind to cellular proteins, lipids, or nucleic acids, potentially leading to cytotoxicity and tissue injury [25]. Similarly, certain alkaloids are metabolized into compounds that place a heavy burden on hepatic detoxification systems, increasing the risk of liver dysfunction, particularly with prolonged exposure or in individuals with impaired hepatic function.

4.3 Tissue Accumulation

Lipophilic phytotherapeutic agents or those with slow elimination rates may accumulate in specific tissues such as the liver, brain, or adipose tissue [26]. Repeated dosing can lead to gradual accumulation, extending biological half-life and increasing the likelihood of delayed toxicity. Vulnerable populations, including children, elderly individuals, and patients with compromised liver or kidney function, are particularly susceptible to adverse effects arising from tissue accumulation [27].

4.4 Herb-Drug Interactions

Herb-drug interactions represent a major safety concern in clinical practice. Many phytotherapeutic agents modulate the activity of metabolic enzymes and drug transporters [28]. Enzyme induction can accelerate the clearance of conventional medications, reducing their therapeutic efficacy, while enzyme inhibition can result in elevated drug concentrations and increased toxicity [29]. Well-documented examples include St. John's Wort reducing plasma levels of oral contraceptives and grapefruit components increasing systemic exposure to drugs metabolized by CYP3A4 [30].

4.5 Individual Differences

Interindividual variability further complicates safety assessment. Genetic polymorphisms, age-related changes in metabolism, and underlying health conditions significantly influence toxicokinetic behavior, underscoring the need for individualized risk assessment when using phytotherapeutic agents [31].

5. Assessing Safety Using Toxicokinetic Data

The safety evaluation of phytotherapeutic agents increasingly depends on robust toxicokinetic data, which provide quantitative insight into systemic exposure, tissue distribution, and elimination patterns [32]. Integrating toxicokinetic analysis into safety assessment allows for more accurate prediction of adverse effects and supports the establishment of evidence-based dosing guidelines.

5.1 Biomarker Monitoring

Biomarker monitoring plays a central role in toxicokinetic safety assessment. Measuring circulating levels of parent phytochemicals and their metabolites enables researchers and clinicians to determine whether concentrations remain within established safe ranges [33]. Monitoring also helps identify the accumulation of potentially harmful metabolites and assess how long compounds persist in systemic circulation. In addition to measuring phytochemical levels, biomarkers of organ function, such as liver enzymes or renal clearance indicators, provide early warning signs of organ stress or toxicity [34]. Together, these biomarkers allow for real-time assessment of both exposure and biological response.

5.2 Dose-Response Relationships

Understanding dose-response relationships is essential for identifying safe and effective dosing regimens. Toxicokinetic studies reveal how increasing doses influence absorption, metabolism, and elimination [35]. Non-linear kinetics, in which small increases in dose produce disproportionately high plasma concentrations, suggest saturation of metabolic or transport mechanisms. Such saturation can markedly increase toxicity risk, particularly during long-term use or in susceptible individuals [36]. Establishing dose thresholds based on toxicokinetic data helps prevent unintended overexposure.

5.3 Advanced Modeling Techniques

Advanced modeling approaches, particularly physiologically based toxicokinetic models, are increasingly used to predict the behavior of phytotherapeutic agents under diverse conditions [37]. These models integrate physiological parameters such as age, sex, body composition, genetic variability in metabolic enzymes, and potential drug interactions [38]. PBTK modeling is especially valuable when clinical safety data are limited, enabling informed risk assessment and guiding future experimental and clinical studies.

CONCLUSION

Phytotherapeutic agents offer valuable antioxidant and therapeutic effects, but their safety cannot be assumed simply because they are "natural." Toxicokinetics - particularly the study of absorption, distribution, metabolism, and excretion - plays a central role in understanding how these compounds interact with the body at different doses and in various physiological conditions. By integrating toxicokinetic data with clinical research and advanced modeling, scientists and healthcare professionals can more effectively balance the antioxidant benefits of phytotherapeutic agents with their potential risks. Ongoing research, improved formulations, personalized approaches, and vigilant safety monitoring are essential to ensuring that plant-derived compounds remain both effective and safe for diverse populations.

REFERENCES

1. Chaachouay N, Zidane L. Plant-Derived Natural Products: A Source for Drug Discovery and Development. *Drugs and Drug Conditions*; 2024; 3(1):184-207. https://doi.org/10.3390/ddc3010011
2. Latif, R., Nawaz, T. Medicinal plants and human health: a comprehensive review of bioactive compounds, therapeutic effects, and applications. *Phytochem Rev* (2025). https://doi.org/10.1007/s11101-025-10194-7
3. Rizvi SAA, Einstein GP, Tulp OL, Sainvil F, Branly R. Introduction to Traditional Medicine and Their Role in Prevention and Treatment of Emerging and Re-Emerging Diseases. *Biomolecules*. 2022; 12(10):1442. https://doi.org/10.3390/biom12101442
4. Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, Squadrito F, Altavilla D, Bitto A. Oxidative Stress: Harms and Benefits for Human Health. Oxid Med Cell Longev. 2017;2017:8416763. doi: 10.1155/2017/8416763. Epub 2017 Jul 27. PMID: 28819546; PMCID: PMC5551541.
5. Garcia-Llorens G, El Ouardi M, Valls-Belles V. Oxidative Stress Fundamentals: Unraveling the Pathophysiological Role of Redox Imbalance in Non-Communicable Diseases. *Applied Sciences*. 2025; 15(18):10191. https://doi.org/10.3390/app151810191
6. Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D, Gargiulo G, Testa G, Cacciatore F, Bonaduce D, Abete P. Oxidative stress, aging, and diseases. Clin Interv Aging. 2018 Apr 26;13:757-772. doi: 10.2147/CIA.S158513. PMID: 29731617; PMCID: PMC5927356.
7. Guo, J., Huang, X., Dou, L. *et al.* Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. *Sig Transduct Target Ther* **7**, 391 (2022). https://doi.org/10.1038/s41392-022-01251-0
8. Dixit R, Riviere J, Krishnan K, Andersen ME. Toxicokinetics and physiologically based toxicokinetics in toxicology and risk assessment. J Toxicol Environ Health B Crit Rev. 2003 Jan-Feb;6(1):1-40. doi: 10.1080/10937400306479. PMID: 12587252.
9. Braeuning A, Marx-Stoelting P. Mixture prioritization and testing: the importance of toxicokinetics. Arch Toxicol. 2021 May;95(5):1863-1864. doi: 10.1007/s00204-021-03026-y. Epub 2021 Mar 17. PMID: 33730198; PMCID: PMC8113307.
10. Bashiardes S, Christodoulou C. Orally Administered Drugs and Their Complicated Relationship with Our Gastrointestinal Tract. *Microorganisms*. 2024; 12(2):242. https://doi.org/10.3390/microorganisms12020242
11. Stielow M, Witczyńska A, Kubryń N, Fijałkowski Ł, Nowaczyk J, Nowaczyk A. The Bioavailability of Drugs—The Current State of Knowledge. *Molecules*. 2023; 28(24):8038. https://doi.org/10.3390/molecules28248038
12. Azman M, Sabri AH, Anjani QK, Mustaffa MF, Hamid KA. Intestinal Absorption Study: Challenges and Absorption Enhancement Strategies in Improving Oral Drug Delivery. Pharmaceuticals (Basel). 2022 Aug 8;15(8):975. doi: 10.3390/ph15080975. PMID: 36015123; PMCID: PMC9412385.
13. Kiela PR, Ghishan FK. Physiology of Intestinal Absorption and Secretion. Best Pract Res Clin Gastroenterol. 2016 Apr;30(2):145-59. doi: 10.1016/j.bpg.2016.02.007. Epub 2016 Feb 10. PMID: 27086882; PMCID: PMC4956471.
14. Bošković J, Dobričić V, Savić J, Rupar J, Aleksić M, Marković B, Čudina O. In Vitro Evaluation of Pharmacokinetic Properties of Selected Dual COX-2 and 5-LOX Inhibitors. *Pharmaceuticals*. 2024; 17(10):1329. https://doi.org/10.3390/ph17101329
15. Barre J, Urien S, Albengres E, Tillement JP. Plasma and tissue binding as determinants of drug body distribution. Possible applications to toxicological studies. Xenobiotica. 1988 Jan;18 Suppl 1:15-20. PMID: 3344588.

16. Almazroo OA, Miah MK, Venkataramanan R. Drug Metabolism in the Liver. Clin Liver Dis. 2017 Feb;21(1):1-20. doi: 10.1016/j.cld.2016.08.001. Epub 2016 Oct 15. PMID: 27842765.
17. Rutkowska M, Witek M, Olszewska MA. A Comprehensive Review of Molecular Mechanisms, Pharmacokinetics, Toxicology and Plant Sources of Juglanin: Current Landscape and Future Perspectives. *International Journal of Molecular Sciences*. 2024; 25(19):10323. https://doi.org/10.3390/ijms251910323
18. 18 Yan Z, Zhou Y, Zhang Y, Zhang X. Distribution, Bioaccumulation, and Risks of Pharmaceutical Metabolites and Their Parents: A Case Study in an Yunliang River, Nanjing City. *International Journal of Environmental Research and Public Health*. 2023; 20(4):2967. https://doi.org/10.3390/ijerph20042967
19. 19 Fleck C, Bräunlich H. Methods in testing interrelationships between excretion of drugs via urine and bile. Pharmacol Ther. 1984;25(1):1-22. doi: 10.1016/0163-7258(84)90022-6. PMID: 6387723.
20. Ghibellini G, Leslie EM, Brouwer KL. Methods to evaluate biliary excretion of drugs in humans: an updated review. Mol Pharm. 2006 May-Jun;3(3):198-211. doi: 10.1021/mp060011k. PMID: 16749853; PMCID: PMC2572858.
21. Huang L, Nie L, Ye X, Lin Z, Liu Y, Wei F. Enterohepatic Recirculation-Mediated Reabsorption of Aristolochic Acid I: Revealed by Toxicokinetics and Metabolite Identification in Rats. *Toxics*. 2025; 13(11):919. https://doi.org/10.3390/toxics13110919
22. Zhang Y, Yi H, Yang H, Song Y, Ren C, Li X, Zhang Y. Herb-Drug Interaction Between Sailuotong and Pitavastatin: A Systematic Pharmacokinetic Investigation and Mechanism Analysis. Drug Des Devel Ther. 2025 Aug 20;19:7135-7149. doi: 10.2147/DDDT.S529385. PMID: 40859972; PMCID: PMC12375325.
23. Mihaylova R, Elincheva V, Momekov G, Simeonova R. Unlocking the Therapeutic Potential of Ellagitannins: A Comprehensive Review of Key Representatives. *Molecules*. 2025; 30(22):4328. https://doi.org/10.3390/molecules30224328
24. Upadhyay S, Dixit M. Role of Polyphenols and Other Phytochemicals on Molecular Signaling. Oxid Med Cell Longev. 2015;2015:504253. doi: 10.1155/2015/504253. Epub 2015 Jun 9. PMID: 26180591; PMCID: PMC4477245.
25. Mahdi L, Graziani A, Baffy G, Mitten EK, Portincasa P, Khalil M. Unlocking Polyphenol Efficacy: The Role of Gut Microbiota in Modulating Bioavailability and Health Effects. *Nutrients*. 2025; 17(17):2793. https://doi.org/10.3390/nu17172793
26. Bas TG. Dietary Polyphenols (Flavonoids) Derived from Plants for Use in Therapeutic Health: Antioxidant Performance, ROS, Molecular Mechanisms, and Bioavailability Limitations. *International Journal of Molecular Sciences*. 2026; 27(3):1404. https://doi.org/10.3390/ijms27031404
27. Teng Z, Yuan C, Zhang F, Huan M, Cao W, Li K, Yang J, Cao D, Zhou S, Mei Q. Intestinal absorption and first-pass metabolism of polyphenol compounds in rat and their transport dynamics in Caco-2 cells. PLoS One. 2012;7(1):e29647. doi: 10.1371/journal.pone.0029647. Epub 2012 Jan 13. PMID: 22253753; PMCID: PMC3258254.
28. Tillman L, Margalef Rieres J, Ahjem E, Bishop-Guest F, McGrath M, Hatrick H, Pranjol MZI. Thinking Outside the Therapeutic Box: The Potential of Polyphenols in Preventing Chemotherapy-Induced Endothelial Dysfunction. *Cells*. 2025; 14(8):566. https://doi.org/10.3390/cells14080566
29. Aatif M. Current Understanding of Polyphenols to Enhance Bioavailability for Better Therapies. Biomedicines. 2023 Jul 24;11(7):2078. doi: 10.3390/biomedicines11072078. PMID: 37509717; PMCID: PMC10377558.
30. Ciupei D, Colişar A, Leopold L, Stănilă A, Diaconeasa ZM. Polyphenols: From Classification to Therapeutic Potential and Bioavailability. *Foods*. 2024; 13(24):4131. https://doi.org/10.3390/foods13244131
31. Teodoro M, Briguglio G, Fenga C, Costa C. Genetic polymorphisms as determinants of pesticide toxicity: Recent advances. Toxicol Rep. 2019 Jun 7;6:564-570. doi: 10.1016/j.toxrep.2019.06.004. PMID: 31293901; PMCID: PMC6595235.
32. Shenfield GM. Genetic polymorphisms, drug metabolism and drug concentrations. Clin Biochem Rev. 2004;25(4):203-6. PMID: 18458715; PMCID: PMC1934960.
33. Chiarella P, Capone P, Sisto R. Contribution of Genetic Polymorphisms in Human Health. *International Journal of Environmental Research and Public Health*. 2023; 20(2):912. https://doi.org/10.3390/ijerph20020912

34. Costa LG, Lovreglio P, Vitalone A, Soleo L. Ruolo del polimorfismo genetico nella valutazione del rischio [Role of genetic polymorphism in risk assessment]. G Ital Med Lav Ergon. 2003 Jul-Sep;25(3):320-7. Italian. PMID: 14582249.
35. Aronica L, Ordovas JM, Volkov A, Lamb JJ, Stone PM, Minich D, Leary M, Class M, Metti D, Larson IA, et al. Genetic Biomarkers of Metabolic Detoxification for Personalized Lifestyle Medicine. *Nutrients*. 2022; 14(4):768. https://doi.org/10.3390/nu14040768
36. Rzeczycki P, Pęciak O, Plust M, Droździk M. Molecular Aspects of Geriatric Pharmacotherapy. *Cells*. 2025; 14(17):1363. https://doi.org/10.3390/cells14171363
37. Mielke H, Gundert-Remy U. Physiologically based toxicokinetic modelling as a tool to support risk assessment: three case studies. J Toxicol. 2012;2012:359471. doi: 10.1155/2012/359471. Epub 2012 May 9. PMID: 22649449; PMCID: PMC3357559.
38. Chen M, Du R, Zhang T, Li C, Bao W, Xin F, Hou S, Yang Q, Chen L, Wang Q, Zhu A. The Application of a Physiologically Based Toxicokinetic Model in Health Risk Assessment. Toxics. 2023 Oct 21;11(10):874. doi: 10.3390/toxics11100874. PMID: 37888724; PMCID: PMC10611306.
39. Ugwu OPC, Offor CE, Ibiam UA, Ezugwu AL, Uraku AJ, Igwe CN. The effect of ethanol extract of Jatropha curcas on renal markers of chloroform intoxicated albino Wistar rats. Eur J Biol Sci. 2015;7(1):21–5.
40. Ugwu OPC, Nzubechukwu E. The effect of ethanol leaf extract of Jatropha curcas on chloroform-induced hepatotoxicity in albino rats. Glob J Biotechnol Biochem. 2015;10:11–5.
41. Ugwu OPC, Onwe SC, Okon MB. The effect of methanol extract of Rauwolfia vomitoria on lipid profile of chloroform-intoxicated Wistar albino rats. IAA J Sci Res. 2022;8(1):73–82.
42. Ugwu OPC. The effect of ethanol leaf extract of Rauwolfia vomitoria on hepatic markers of chloroform-intoxicated albino Wistar rats. IAA J Appl Sci. 2022;8(1):87–97.
43. Ugwu OPC. The effect of methanol leaf extract of Rauwolfia vomitoria on hepatic markers of chloroform-intoxicated albino Wistar rats. IAA J Appl Sci. 2022;8(1):76–86.
44. Aja PM, Ezeudeh NL, Umahi BG, Ugwu OPC, Enechi OC, Edwin N, et al. Hepato-protective effect of ethanol extract of Pterocarpus santalinoides leaf on carbon tetrachloride (CCl4)-induced albino rats. Caribb J Sci Technol. 2016;4(1):882–95.
45. Enechi OC, Okpe CC, Ibe GN, Omeje KO, Ugwu OPC. Effect of Buchholzia coriacea methanol extract on haematological indices and liver function parameters in Plasmodium berghei-infected mice. Global Vet. 2016;16(1):57–66.
46. Offor CE, Ibiam UA, Ugwu PC, Nwankwo H. The effect of ethanol leaf-extract of Gmelina arborea on liver enzymes. Eur J Biol Sci. 2015;7(1):38–40.
47. Offor CE, Nwankwegu NJ, Ugwu OPC, Aja PM. The effects of ethanol leaf-extract of Pterocarpus santalinoides on liver enzymes of albino rats. 2015.
48. Aja PM, Udeh SMC, Opajobi AO, Uzuegbu UE, Alum EU, Edwin N, et al. Hepato-protective effect of aqueous leaf-extract of Talinum triangulare in monosodium glutamate (MSG)-induced hepatic damage in albino rats. Indo Am J Pharm Sci. 2017;4(2):464–70.
49. Alum EU, Umoru GU, Uti DE, Aja PM, Ugwu OPC, Orji OU, et al. Hepato-protective effect of ethanol leaf extract of Datura stramonium in alloxan-induced diabetic albino rats. J Chem Soc Nigeria. 2022;47(5).
50. Orji OU, Ibiam UA, Aja PM, Uraku AJ, Inya-Agha OR, Ugwu OPC, et al. Hepatoprotective activity of ethanol extract of Vernonia ambigua against carbon tetrachloride-induced hepatotoxicity in albino rats. IOSR J Dent Med Sci. 2015;14:22–9.
51. Orji OU, Ibiam UA, Aloke C, Awoke J, Aja PM, Ugwu OPC, et al. Biochemical assessment of ethanol leaf extract of Cnidoscolus aconitifolius on liver integrity of albino rat treated with lead. Glob J Pharmacol. 2016;10(4):108–13.
52. Ezekwe CI, Ada AC, Ugwu OPC. Effects of methanol extract of Parkia biglobosa stem bark on the liver and kidney functions of albino rats. 2013.
53. Ezekwe CI, Uzomba CR, Ugwu OPC. The effect of methanol extract of Talinum triangulare (water leaf) on the hematology and some liver parameters of experimental rats. Glob J Biotechnol Biochem. 2013;8(2):51–60.

ONLINE ISSN: 2992-5797
PRINT ISSN: 2992-6122

54. Ugwu OPC, Amasiorah VI. Review on health implications, benefits and biochemistry of alcohol intoxication. INOSR Exp Sci. 2020;6(1):62–74.
55. Ezeonwumelu JOC, Uhama KC, Ugwu OPC, Alum EU. Comprehensive overview of alcohol intoxication: mechanisms, effects, and interventions. Res Invent J Sci Exp Sci. 2024;3(1):12–20.
56. Nwaka AC, Ikechi-Agba MC, Ugwu OPC, Igwenyi IO, Agbafor KN, Ibiam UA, et al. The effects of ethanol extracts of Jatropha curcas on some hematological parameters of chloroform intoxicated rats. Am-Eur J Sci Res. 2015;10(1):45–9.
57. Ibiam UA, Ama-Udu, Egwu OA, Ugwu OPC. The protective effect of Gongronema latifolium leaf extract against hepatotoxicity of Rambo and Baygon mosquito coil smoke respectively in albino rats. World Appl Sci J. 2015;33(12):1915–22.
58. Odo CE, Nwodo OFC, Joshua PE, Ubani CS, Etim OE, Ugwu OPC. Effects of Bonny light crude oil on anti-oxidative enzymes and total proteins in Wistar rats. Afr J Biotechnol. 2012;11(98):16455–60.
59. Ozioko PC, Ugwu OPC, Chilaka FC, Ude S. Purification and characterization of beta-D-glucosidase from the digestive tracts of an African Giant Snail (Achatina achatina). 2013.
60. Ozioko PC, Ikeyi AP, Ugwu OPC. Review article: cellulases, their substrates, activity and assay methods. Exp. 2013;12(2):778–85.
61. Ezekwe CI, Okorie A, Ugwu OPC, Nwodo OFC, Egba SC. Blood pressure lowering effect of extract of Gongronema latifolium. Res J Pharm Biol Chem Sci. 2014;5(2):952.

CITE AS: Zakaria Ali (2026). Toxicokinetics of Phytotherapeutic Agents: Balancing Antioxidant Activity with Safety. NEWPORT INTERNATIONAL JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 7(2):66-72. https://doi.org/10.59298/NIJBAS/2026/7.2.6672